Elvitegravir

Elvitegravir belongs to the class of antiretroviral drugs known as integrase inhibitors. The drug works against HIV's integrase protein, blocking its ability to integrate its genetic code into human cells.

As an individual drug (Vitekta), elvitegravir was given marketing approval in Europe in November 2013. However, marketing authorisation was removed at the request of the drug's maker, Gilead Sciences, in late 2016. Gilead decided to stop marketing the drug for commercial reasons.

Elvitegravir is still available as part of the combination products Stribild (combined with tenofovir disoproxil, emtricitabine and cobicistat) and Genvoya (combined with tenofovir alafenamide, emtricitabine and cobicistat).

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.